AGP Executive Report
Last update: 7 hours agoDrug Safety: The FDA is requiring GLP-1 makers to warn about a possible risk of NAION, a rare eye condition that can cause sudden vision loss. Patients who notice symptoms should contact a health professional promptly. Stroke Prevention: The FDA approved Bayer’s asundexian, the first Factor XIa inhibitor, to reduce recurrent stroke risk in certain adults when used with antiplatelet therapy. Digital Mental Health: Amwell and UCLA will study digital cognitive behavioral therapy to help veterans, particularly those in rural areas, access depression care. Eye Infection: A 23-year study of post-cataract infections found cefuroxime resistance rose from 26% to 66.1%, underscoring the need to track changing bacteria and drug susceptibility.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
![<![CDATA[Q&A: Antiretroviral Formulary Protocol Cuts Costs, Eases Workflow]]>](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/30237291-955875693-fc82c36a6b61d964b8dc6351e4018c24ac530d9b-1800x1200-200x133.jpeg)
![<![CDATA[France Remains One of Europe’s Leading Biotech Funding Hubs]]>](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/30229720-955818250-1fe371326b0df8ad7666b48cbe798d30f33681c1-1280x720-200x113.jpeg)
![<![CDATA[FDA Adds NAION Eye Risk Warning to All GLP-1 Labels]]>](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/30237289-955875719-b5b05984cdd7b8215e4a696cf9de518998edb190-1800x1200-200x133.jpeg)
